The Role of RNA m6A Modification in Cancer Glycolytic Reprogramming-Reference-Cited by-同舟云学术

The Role of RNA m6A Modification in Cancer Glycolytic Reprogramming

Published:2023-02 Issue:1 Volume:23 Page:51-59
ISSN:1566-5232
Container-title:Current Gene Therapy
language:en
Short-container-title:CGT

Author:

Zhou You¹²³,Huang Tao⁴,Jiang Jingting¹²⁵,Li Yuanqi⁶²⁵,Huang Hao¹²⁵,Wu Shaoxian¹²⁵

Affiliation:

1. Tumor Biological Diagnosis and Treatment Center, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

2. Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, China

3. Institute of Cell Therapy, Soochow University, Changzhou 213003, China;

4. Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China

5. Institute of Cell Therapy, Soochow University, Changzhou 213003, China

6. Tumor Biological Diagnosis and Treatment Center, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

Abstract

Abstract: As one of the main characteristics of neoplasia, metabolic reprogramming provides nutrition and energy to enhance cell proliferation and maintain environment homeostasis. Glycolysis is one of the most important components of cancer metabolism and the Warburg effect contributes to the competitive advantages of cancer cells in the threatened microenvironment. Studies show strong links between N6-methyladenosine (m6A) modification and metabolic recombination of cancer cells. As the most abundant modification in eukaryotic RNA, m6A methylation plays important roles in regulating RNA processing, including splicing, stability, transportation, translation and degradation. The aberration of m6A modification can be observed in a variety of diseases such as diabetes, neurological diseases and cancers. This review describes the mechanisms of m6A on cancer glycolysis and their applications in cancer therapy and prognosis evaluation, aiming to emphasize the importance of targeting m6A in modulating cancer metabolism.

Funder

National Natural Science Foundation of China

Strategic Priority Research Program of Chinese Academy of Sciences

Scientific and Technological Project of Changzhou

Young Talent Development Plan of Changzhou Health Commission

Publisher

Bentham Science Publishers Ltd.

Subject

Genetics (clinical),Drug Discovery,Genetics,Molecular Biology,Molecular Medicine

Reference115 articles.

1. Elia I.; Haigis M.C.; Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism. Nat Metab 2021,3(1),21-32

2. Xia L.; Oyang L.; Lin J.; The cancer metabolic reprogramming and immune response. Mol Cancer 2021,20(1),28

3. Hsu P.P.; Sabatini D.M.; Cancer cell metabolism: Warburg and beyond. Cell 2008,134(5),703-707

4. Koppenol W.H.; Bounds P.L.; Dang C.V.; Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011,11(5),325-337

5. Lunt S.Y.; Vander Heiden M.G.; Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011,27(1),441-464

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications;Biomedicine & Pharmacotherapy;2023-11

2. Novel insight into RNA modifications in tumor immunity: Promising targets to prevent tumor immune escape;The Innovation;2023-07

3. The emerging importance role of m6A modification in liver disease;Biomedicine & Pharmacotherapy;2023-06